A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...

Poorly controlled asthma during pregnancy can lead to serious complications, such as low birth weight, preterm delivery, and ...

North America severe asthma market is set for growth, driven by high asthma prevalence, increased awareness, and advanced treatment options for severe cases. NEWARK, DE, UNITED STATES, January 9 ...

Researchers at McMaster University have made an important discovery in the field of asthma research, identifying a new ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Asthma biologics can be used during pregnancy to reduce the risk of complications associated with the disease. Apostolos ...

(MENAFN- EIN Presswire) Leading companies such as Novartis, Roche, Teva, and Merck are driving advancements in Severe Asthma treatments to enhance patient care. LAS VEGAS , NV, UNITED STATES ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

The global aspergillosis treatment market, valued at USD 3,055.88 million in 2022, is poised for robust growth in the coming ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...